Clene (CLNN) Stock Price, News & Analysis

Company Overview

Clene Inc. (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases. The company’s platform uses nanocrystals designed to influence cellular energy production and protect or restore the function of nerve cells.

Clene’s leading investigational product is CNM-Au8, an orally administered suspension containing catalytically active gold nanocrystals. The therapy is being evaluated in clinical studies for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease. Clene’s research programs are aimed at addressing underlying cellular energy deficits that may contribute to neurodegeneration.

Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities through collaborations and clinical trials involving patients in the United States and other regions. The company’s chief executive officer is Rob Etherington, who has led Clene’s efforts to advance its nanotherapeutics platform and clinical programs.

Key Stats

• Today's Range: $4.01 to $4.37
• 50-Day Range: $3.28 to $5.85
• 52-Week Range: $3.25 to $13.50
• Volume: 63,099 shs
• Average Volume: 230,700 shs
• Market Capitalization: $53.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Moderate Buy

Clene Stock Analysis - MarketRank™

Clene scored higher than 52% of companies evaluated by MarketBeat, and ranked 505th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Clene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Clene has a consensus price target of $34.00, representing about 731.3% upside from its current price of $4.09.

Amount of Analyst Coverage

Clene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Clene are expected to grow in the coming year, from ($1.70) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clene is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clene is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.83% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 5.15.

Change versus previous month

Short interest in Clene has recently decreased by 5.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clene does not currently pay a dividend.

Dividend Growth

Clene does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.60

News Sentiment

Clene has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Clene this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Clene insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

23.28% of the stock of Clene is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/28/2026
• Lytham Partners Fall 2026 Investor Conference: 9/29/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CLNN
• CIK: 1822791
• Web: clene.com
• Phone: 801-676-9695
• Fax: N/A
• Employees: 79
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Clene: $34.00
• High Price Target: $48.00
• Low Price Target: $23.00
• Potential Upside/Downside: +731.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: -20,063.96%
• Pretax Margin: -20,059.90%
• Return on Equity: N/A
• Return on Assets: -137.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.07
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $200 thousand
• Price / Sales: 265.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.62) per share
• Price / Book: -2.52

Miscellaneous

• Outstanding Shares: 12,990,000
• Free Float: 9,317,000
• Market Cap: $53.13 million
• Optionable: No Data
• Beta: 0.95